
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO – Free Report) – Investment analysts at HC Wainwright raised their FY2026 earnings estimates for Agios Pharmaceuticals in a note issued to investors on Friday, November 6th. HC Wainwright analyst D. Tsao now forecasts that the biopharmaceutical company will post earnings of ($5.58) per share for the year, up from their prior forecast of ($6.05). HC Wainwright has a “Buy” rating and a $62.00 price objective on the stock. The consensus estimate for Agios Pharmaceuticals’ current full-year earnings is ($5.72) per share. HC Wainwright also issued estimates for Agios Pharmaceuticals’ Q4 2026 earnings at ($1.12) EPS, FY2027 earnings at ($3.86) EPS, FY2028 earnings at ($1.84) EPS, FY2029 earnings at ($0.07) EPS and FY2030 earnings at $2.01 EPS.
Agios Pharmaceuticals (NASDAQ:AGIO – Get Free Report) last posted its quarterly earnings data on Thursday, November 5th. The biopharmaceutical company reported ($1.09) earnings per share for the quarter, topping the consensus estimate of ($1.24) by $0.15. Agios Pharmaceuticals had a negative net margin of 264.76% and a negative return on equity of 34.63%. The company had revenue of $55.39 million during the quarter, compared to analyst estimates of $51.65 million.
Check Out Our Latest Analysis on AGIO
Agios Pharmaceuticals Price Performance
Shares of AGIO opened at $32.82 on Tuesday. The company has a market capitalization of $1.96 billion, a P/E ratio of -5.19 and a beta of 0.66. Agios Pharmaceuticals has a one year low of $22.24 and a one year high of $46.00. The business’s 50 day simple moving average is $33.17 and its 200-day simple moving average is $31.82.
Insider Activity at Agios Pharmaceuticals
In other news, insider Sarah Gheuens sold 7,866 shares of the stock in a transaction that occurred on Monday, October 26th. The shares were sold at an average price of $37.69, for a total transaction of $296,469.54. Following the sale, the insider directly owned 54,645 shares of the company’s stock, valued at $2,059,570.05. This represents a 12.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 9,855 shares of company stock worth $371,112 over the last quarter. 5.40% of the stock is owned by corporate insiders.
Institutional Inflows and Outflows
Several institutional investors have recently bought and sold shares of the stock. BlackRock Inc. acquired a new position in Agios Pharmaceuticals during the 2nd quarter worth $239,582,000. Assenagon Asset Management S.A. increased its stake in shares of Agios Pharmaceuticals by 1,714.6% in the 3rd quarter. Assenagon Asset Management S.A. now owns 1,886,412 shares of the biopharmaceutical company’s stock valued at $62,723,000 after buying an additional 1,782,457 shares during the period. ADAR1 Capital Management LLC acquired a new stake in shares of Agios Pharmaceuticals in the 2nd quarter valued at $47,800,000. Parkman Healthcare Partners LLC acquired a new stake in shares of Agios Pharmaceuticals in the 2nd quarter valued at $24,828,000. Finally, SCS Capital Management LLC bought a new stake in shares of Agios Pharmaceuticals during the second quarter worth $22,743,000.
Key Headlines Impacting Agios Pharmaceuticals
These are some of the AGIO headlines that stood out recently:
- Positive Sentiment: HC Wainwright raised its EPS estimates across 2026–2030, projecting losses to narrow and turning profitable in 2030, with EPS of $2.01 versus its earlier $0.72 estimate. The firm reiterated its Buy rating and $62 price target. Agios Pharmaceuticals analyst estimates
- Neutral Sentiment: A report described a sharp increase in short interest but also stated that short interest totaled zero shares, making the data internally inconsistent; it does not establish meaningful short-selling pressure. Agios Pharmaceuticals short-interest information
- Neutral Sentiment: Agios published its Q3 2026 earnings-call presentation, but the supplied entry contains no details about the results or guidance, so its market implications cannot be assessed from this information. Agios Pharmaceuticals Q3 2026 earnings-call presentation
Agios Pharmaceuticals Company Profile
Agios Pharmaceuticals is a biopharmaceutical company focused on developing medicines for rare genetic diseases, particularly blood disorders. Based in Cambridge, Massachusetts, the company applies research into cellular metabolism to identify potential treatments. Its marketed medicine, PYRUKYND (mitapivat), is approved in the United States to treat adults with pyruvate kinase deficiency, a rare inherited disorder that can cause anemia. Agios also develops therapies for other rare diseases, including additional blood disorders.
See Also
- Five stocks we like better than Agios Pharmaceuticals
- Keeping AI Cool: AAON Rides the AI Heatwave to Record Growth
- AST SpaceMobile Has a New Rocket Plan, But Its Cash-Burn Problem Isn’t Going Away
- Powering Up the Moon: Redwire’s $40 Million NASA Award
- Can Constellation Energy’s Contracts Power a Stock Rebound?
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
